Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

292
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
292
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

796
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
796
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

445
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
445
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

870
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
870
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

711
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
711
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

406
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
406

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The burden of steroid use in systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026
Same author

Interdisciplinary Clinical Practice Guidelines for patient-centred management of juvenile-onset systemic lupus erythematosus.

EULAR rheumatology open·2026
Same author

The V158F polymorphism in human FcγRIIIa/CD16a defines opposing receptor responses when interacting with soluble immune complexes.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Belimumab induces early and sustained resolution of lupus thrombocytopenia.

Lupus science & medicine·2026
Same author

Zeitschrift fur Rheumatologie·2026
Same author

Beyond screening for pulmonary arterial hypertension: The DETECT score is a potential promising prediction tool for all-cause mortality in systemic sclerosis: Analysis from the EUSTAR database.

Journal of autoimmunity·2026
Same journal

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

["Not everything that looks like a tumor..." - Pulmonary tularemia with hilar lymphadenopathy].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Emergency management of sickle cell disease].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Hereditary dehydrated stomatocytosis (= hereditary xerocytosis) - Interesting hummingbird or clinically relevant diagnosis?]

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Diagnosis of Congenital Hemolytic Anemias in Adults].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[46-year-old female patient with right upper abdominal pain].

Deutsche medizinische Wochenschrift (1946)·2026
See all related articles

Related Experiment Video

Updated: Mar 11, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.8K

[Lupus erythematosus - Update 2016].

Martin Aringer, Reinhard Edmund Voll

    Deutsche Medizinische Wochenschrift (1946)
    |December 1, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Systemic lupus erythematosus (SLE) treatment advances are slow, with limited new drug approvals. Ongoing clinical trials and developing treatment goals offer future hope for SLE management.

    More Related Videos

    Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
    05:44

    Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

    Published on: June 10, 2025

    1.4K
    Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
    05:39

    Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

    Published on: May 16, 2025

    787

    Related Experiment Videos

    Last Updated: Mar 11, 2026

    The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
    12:04

    The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

    Published on: November 1, 2015

    18.8K
    Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
    05:44

    Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

    Published on: June 10, 2025

    1.4K
    Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
    05:39

    Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

    Published on: May 16, 2025

    787

    Area of Science:

    • Rheumatology
    • Immunology
    • Pharmacology

    Background:

    • Belimumab, the first biologic for SLE, was approved five years ago, yet no new drug candidates are nearing approval.
    • Limited clinical trial data exist for novel oral anticoagulants in antiphospholipid syndrome.
    • Reimbursement decisions for mycophenolate mofetil (MMF) in lupus nephritis are pending despite strong evidence.

    Purpose of the Study:

    • To review the current landscape of SLE drug development and treatment strategies.
    • To highlight ongoing clinical trials with potential to advance SLE therapy.
    • To discuss the development of new classification criteria and treatment goals for SLE.

    Main Methods:

    • Review of recent clinical trial data and regulatory approvals for SLE treatments.
    • Analysis of ongoing research in rheumatology and immunology related to SLE.
    • Examination of initiatives to establish standardized treatment goals and classification criteria.

    Main Results:

    • Few SLE drug candidates are close to approval, indicating a slow advancement in therapeutic options.
    • Validated tools exist for assessing treatment efficacy in SLE clinical trials.
    • Significant efforts are underway to define treatment targets and refine classification criteria for SLE.

    Conclusions:

    • Despite challenges, ongoing research and development hold promise for future SLE treatment advancements.
    • The development of validated assessment tools and standardized criteria is crucial for future SLE research.
    • Further research and regulatory support are needed to bring new SLE therapies to patients.